Cocrystal Pharma, Inc. SEC filings COCP
Cocrystal Pharma, Inc. has 672 filings in SEC EDGAR's recent list, going back to Sep 20, 2007. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 9, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 1, 2026 | — |
| CORRESP | Letter to the SEC | Apr 29, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2026 | — |
| EFFECT | Filing | Sep 25, 2025 | — |
| CORRESP | Letter to the SEC | Sep 25, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2025 | — |
| CORRESP | Letter to the SEC | Aug 13, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 30, 2025 | — |
| EFFECT | Filing | May 26, 2023 | — |
| CORRESP | Letter to the SEC | May 24, 2023 | — |
| UPLOAD | Letter from the SEC | May 19, 2023 | — |
| EFFECT | Filing | May 13, 2020 | — |
| CORRESP | Letter to the SEC | May 12, 2020 | — |
| CORRESP | Letter to the SEC | May 11, 2020 | — |
| CORRESP | Letter to the SEC | May 4, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2020 | — |
| EFFECT | Filing | May 22, 2019 | — |
| CORRESP | Letter to the SEC | May 20, 2019 | — |
| UPLOAD | Letter from the SEC | May 2, 2019 | — |
| CT ORDER | Filing | Apr 30, 2019 | — |
| NT 10-K | Filing | Mar 19, 2019 | Dec 31, 2018 |
| NT 10-K | Filing | Mar 19, 2018 | Dec 31, 2017 |
| CERT | Filing | Mar 9, 2018 | — |
| 8-A12B | Filing | Mar 9, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2017 | — |
| CORRESP | Letter to the SEC | Oct 12, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2017 | — |
| EFFECT | Filing | Oct 10, 2017 | — |
| CORRESP | Letter to the SEC | Oct 5, 2017 | — |
| CORRESP | Letter to the SEC | Oct 5, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2017 | — |
| D | Filing | May 2, 2017 | — |
| NT 10-K | Filing | Mar 17, 2017 | Dec 31, 2016 |
| D | Filing | Sep 15, 2016 | — |
| RW | Withdrawal of registration statement request | Jul 15, 2016 | — |
| D | Filing | Mar 30, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2015 | — |
| CORRESP | Letter to the SEC | Jun 1, 2015 | — |
| UPLOAD | Letter from the SEC | May 28, 2015 | — |
| CT ORDER | Filing | Jun 26, 2014 | — |
| NT 10-K | Filing | Apr 1, 2014 | Dec 31, 2013 |
| 8-A12G | 8a-12g | Mar 17, 2014 | — |
| D | Filing | Jan 31, 2014 | — |
| D | Filing | Jan 17, 2014 | — |
| NT 10-Q/A | Filing | Nov 13, 2013 | Sep 30, 2013 |
| NT 10-Q | Filing | Nov 12, 2013 | Sep 30, 2013 |
| D | Filing | Nov 5, 2013 | — |
| D | Filing | Sep 5, 2013 | — |
| NT 10-Q | Filing | Aug 6, 2013 | Jun 30, 2013 |
| D | Filing | Apr 22, 2013 | — |
| NT 10-K | Filing | Mar 18, 2013 | Dec 31, 2012 |
| EFFECT | Filing | Feb 14, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2013 | — |
| CORRESP | Letter to the SEC | Feb 13, 2013 | — |
| CORRESP | Letter to the SEC | Feb 13, 2013 | — |
| CORRESP | Letter to the SEC | Feb 12, 2013 | — |
| CORRESP | Letter to the SEC | Feb 8, 2013 | — |
| CT ORDER | Filing | Feb 4, 2013 | — |
| CORRESP | Letter to the SEC | Jan 31, 2013 | — |
| UPLOAD | Letter from the SEC | Jan 24, 2013 | — |
| CORRESP | Letter to the SEC | Jan 14, 2013 | — |
| CORRESP | Letter to the SEC | Jan 9, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2012 | — |
| CORRESP | Letter to the SEC | Nov 13, 2012 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2012 | — |
| CORRESP | Letter to the SEC | Sep 28, 2012 | — |
| CORRESP | Letter to the SEC | Sep 21, 2012 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2012 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2012 | — |
| D | Filing | Jun 25, 2012 | — |
| D | Filing | May 29, 2012 | — |
| NT 10-Q | Filing | May 15, 2012 | Mar 31, 2012 |
| D | Filing | Apr 26, 2012 | — |
| D | Filing | Apr 25, 2012 | — |
| D | Filing | Apr 25, 2012 | — |
| D | Filing | Apr 25, 2012 | — |
| NT 10-K | Filing | Mar 30, 2012 | Dec 31, 2011 |
| D | Filing | Mar 20, 2012 | — |
| D | Filing | Mar 9, 2012 | — |
| D | Filing | Jan 26, 2012 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2012 | — |
| CORRESP | Letter to the SEC | Dec 19, 2011 | — |
| NT 10-Q | Filing | Nov 14, 2011 | Sep 30, 2011 |
| UPLOAD | Letter from the SEC | Oct 18, 2011 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2011 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2011 | — |
| NT 10-Q | Filing | Aug 15, 2011 | Jun 30, 2011 |
| NT 10-Q | Biozone form 12b-25 form 10-q 03/31/11 | May 16, 2011 | Mar 31, 2011 |
| EFFECT | Filing | Aug 5, 2010 | — |
| CORRESP | Letter to the SEC | Jul 29, 2010 | — |
| UPLOAD | Letter from the SEC | Jul 27, 2010 | — |
| NT 10-K | Isri form 12b25 03/30/10 | Mar 31, 2010 | Dec 31, 2009 |
| 10KSB | Annual report | Mar 28, 2008 | Dec 31, 2007 |
| 10QSB | Quarterly report | Nov 9, 2007 | Sep 30, 2007 |
| EFFECT | Filing | Oct 4, 2007 | — |
| SB-2 | Registration statement | Sep 20, 2007 | — |
Showing 100 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COCP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1412486
- Former names
- BIOZONE PHARMACEUTICALS, INC. (until Mar 25, 2014); International Surf Resorts, Inc. (until Mar 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.